Cargando…

Intestinal Fatty Acid Binding Protein, a Biomarker of Intestinal Barrier, is Associated with Severity of Psoriasis

Alterations of intestinal microbiota play a significant role in the pathogenesis of psoriasis. Dysbiosis may cause disruption of the intestinal barrier, which contributes to immune activation by translocation of microbial antigens and metabolites. Intestinal fatty acid binding protein (I-FABP) serve...

Descripción completa

Detalles Bibliográficos
Autores principales: Sikora, Mariusz, Stec, Albert, Chrabaszcz, Magdalena, Waskiel-Burnat, Anna, Zaremba, Michal, Olszewska, Malgorzata, Rudnicka, Lidia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678629/
https://www.ncbi.nlm.nih.gov/pubmed/31336842
http://dx.doi.org/10.3390/jcm8071021
_version_ 1783441146272284672
author Sikora, Mariusz
Stec, Albert
Chrabaszcz, Magdalena
Waskiel-Burnat, Anna
Zaremba, Michal
Olszewska, Malgorzata
Rudnicka, Lidia
author_facet Sikora, Mariusz
Stec, Albert
Chrabaszcz, Magdalena
Waskiel-Burnat, Anna
Zaremba, Michal
Olszewska, Malgorzata
Rudnicka, Lidia
author_sort Sikora, Mariusz
collection PubMed
description Alterations of intestinal microbiota play a significant role in the pathogenesis of psoriasis. Dysbiosis may cause disruption of the intestinal barrier, which contributes to immune activation by translocation of microbial antigens and metabolites. Intestinal fatty acid binding protein (I-FABP) serves as a biomarker of enterocyte damage. The aim of this study was to investigate clinical and metabolic factors affecting plasma concentration of I-FABP in patients with psoriasis. Eighty patients with psoriasis and 40 control subjects were enrolled in the study. Serum I-FABP (243.00 (108.88–787.10) vs. 114.38 (51.60–241.60) pg/ml, p < 0.001) and neutrophil to lymphocyte ratio (NLR; 2.59 (1.96–3.09) vs. 1.72 (1.36–47 2.11), p < 0.01) were significantly increased in patients with psoriasis compared to controls. A significant positive correlation was found between I-FABP and body mass index (BMI) (r = 0.82, p < 0.001), Psoriasis Area Severity Index (PASI) (r = 0.78, p < 0.001) and neutrophil to lymphocyte ratio (NLR) (r = 0.24, p < 0.001). Rising quartiles of I-FABP were associated with increasing values of BMI, PASI and NLR. The results of the logistic regression model confirmed an increased risk of higher disease severity with I-FABP concentration – odds ratio 3.34 per 100 pg/mL I-FABP increase. In conclusion, intestinal integrity in patients with psoriasis is affected by obesity, severity of the disease and systemic inflammation. The modulation of gut barrier may represent a new therapeutic approach for psoriasis.
format Online
Article
Text
id pubmed-6678629
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-66786292019-08-19 Intestinal Fatty Acid Binding Protein, a Biomarker of Intestinal Barrier, is Associated with Severity of Psoriasis Sikora, Mariusz Stec, Albert Chrabaszcz, Magdalena Waskiel-Burnat, Anna Zaremba, Michal Olszewska, Malgorzata Rudnicka, Lidia J Clin Med Article Alterations of intestinal microbiota play a significant role in the pathogenesis of psoriasis. Dysbiosis may cause disruption of the intestinal barrier, which contributes to immune activation by translocation of microbial antigens and metabolites. Intestinal fatty acid binding protein (I-FABP) serves as a biomarker of enterocyte damage. The aim of this study was to investigate clinical and metabolic factors affecting plasma concentration of I-FABP in patients with psoriasis. Eighty patients with psoriasis and 40 control subjects were enrolled in the study. Serum I-FABP (243.00 (108.88–787.10) vs. 114.38 (51.60–241.60) pg/ml, p < 0.001) and neutrophil to lymphocyte ratio (NLR; 2.59 (1.96–3.09) vs. 1.72 (1.36–47 2.11), p < 0.01) were significantly increased in patients with psoriasis compared to controls. A significant positive correlation was found between I-FABP and body mass index (BMI) (r = 0.82, p < 0.001), Psoriasis Area Severity Index (PASI) (r = 0.78, p < 0.001) and neutrophil to lymphocyte ratio (NLR) (r = 0.24, p < 0.001). Rising quartiles of I-FABP were associated with increasing values of BMI, PASI and NLR. The results of the logistic regression model confirmed an increased risk of higher disease severity with I-FABP concentration – odds ratio 3.34 per 100 pg/mL I-FABP increase. In conclusion, intestinal integrity in patients with psoriasis is affected by obesity, severity of the disease and systemic inflammation. The modulation of gut barrier may represent a new therapeutic approach for psoriasis. MDPI 2019-07-12 /pmc/articles/PMC6678629/ /pubmed/31336842 http://dx.doi.org/10.3390/jcm8071021 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sikora, Mariusz
Stec, Albert
Chrabaszcz, Magdalena
Waskiel-Burnat, Anna
Zaremba, Michal
Olszewska, Malgorzata
Rudnicka, Lidia
Intestinal Fatty Acid Binding Protein, a Biomarker of Intestinal Barrier, is Associated with Severity of Psoriasis
title Intestinal Fatty Acid Binding Protein, a Biomarker of Intestinal Barrier, is Associated with Severity of Psoriasis
title_full Intestinal Fatty Acid Binding Protein, a Biomarker of Intestinal Barrier, is Associated with Severity of Psoriasis
title_fullStr Intestinal Fatty Acid Binding Protein, a Biomarker of Intestinal Barrier, is Associated with Severity of Psoriasis
title_full_unstemmed Intestinal Fatty Acid Binding Protein, a Biomarker of Intestinal Barrier, is Associated with Severity of Psoriasis
title_short Intestinal Fatty Acid Binding Protein, a Biomarker of Intestinal Barrier, is Associated with Severity of Psoriasis
title_sort intestinal fatty acid binding protein, a biomarker of intestinal barrier, is associated with severity of psoriasis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678629/
https://www.ncbi.nlm.nih.gov/pubmed/31336842
http://dx.doi.org/10.3390/jcm8071021
work_keys_str_mv AT sikoramariusz intestinalfattyacidbindingproteinabiomarkerofintestinalbarrierisassociatedwithseverityofpsoriasis
AT stecalbert intestinalfattyacidbindingproteinabiomarkerofintestinalbarrierisassociatedwithseverityofpsoriasis
AT chrabaszczmagdalena intestinalfattyacidbindingproteinabiomarkerofintestinalbarrierisassociatedwithseverityofpsoriasis
AT waskielburnatanna intestinalfattyacidbindingproteinabiomarkerofintestinalbarrierisassociatedwithseverityofpsoriasis
AT zarembamichal intestinalfattyacidbindingproteinabiomarkerofintestinalbarrierisassociatedwithseverityofpsoriasis
AT olszewskamalgorzata intestinalfattyacidbindingproteinabiomarkerofintestinalbarrierisassociatedwithseverityofpsoriasis
AT rudnickalidia intestinalfattyacidbindingproteinabiomarkerofintestinalbarrierisassociatedwithseverityofpsoriasis